Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Technetium-99m is a short-lived form of Technetium-99, an isotope of technetium. It is found as a component of nuclear waste and is used as a medical diagnostic tool. It is used as a radioactive tracer and can be detected in the body by medical equipment such as gamma cameras and Single Photon Emission Computed Tomography (SPECT).

MEA technetium-99m market is estimated to account for US$ 394.6 Mn in terms of value and is expected to reach US$ 688.5 Mn by the end of 2027.

MEA Technetium-99m Market: Drivers

High prevalence of congenital heart disease is expected to propel growth of MEA technetium-99m market over the forecast period. For instance, according to the study, ‘Patterns, prevalence, risk factors, and survival of newborns with congenital heart defects in a Saudi population: a three-year, cohort case-control study’, published in March 2019, the prevalence of congenital heart defects was 14.8/1000 births in the study population.

Moreover, increasing investment in the production of molybdenum-99 is also expected to aid in growth. For instance, in July 2019, NorthStar Medical Radioisotopes, LLC announced completion of construction on its 20,000 square foot molybdenum-99 processing facility.

Gamma Camera held dominant position in MEA technetium-99m market in 2019, accounting for 57.3% share in terms of volume, followed by SPECT, respectively.

Figure 1. MEA Technetium-99m Market Share (%), by Value, by Isotopic Application, 2019

MEA Technetium-99m  | Coherent Market Insights

MEA Technetium-99m Market: Restraints

Availability of 99mTc depends on the production of Mo-99 from the small number of nuclear reactors worldwide. The major producing reactors have already aged and on the verge of shutting down. This creates an issue related to production disruption assuming the need for extended shutdowns for planned or unplanned maintenance work, which is expected to hinder growth of MEA technetium-99m market.

Adoption of alternative imaging modalities is also expected to limit growth of the market. The expected shortage of Tc-99m in the near future has led to increase in adoption of PET or other imaging modalities.

MEA Technetium-99m Market: Opportunities 

Increasing adoption of dual modality imaging technique or hybrid imaging is expected to offer lucrative growth opportunities for players in MEA technetium-99m market. The adoption of hybrid imaging consisting of single-photon emission computed tomography (SPECT) and X-ray transmission computed tomography (CT) scan is increasing globally as it offers short acquisition time and provides accurate attenuation correction and fusion imaging leading to increase in diagnostic sensitivity and specificity.

Moreover, non-reactor production of Mo-99 without using highly enriched uranium is also expected to aid in growth of the market.

MEA technetium-99m market was valued at US$ 394.6 Mn in 2019 and is forecast to reach a value of US$ 688.5 Mn by 2027 at a CAGR of 8.3% between 2020 and 2027.

Figure 2. MEA Technetium-99m Market Value (US$ Mn), and Y-o-Y Growth (%), 2019-2027

MEA Technetium-99m  | Coherent Market Insights

Market Trends/Key Takeaways

Players in the market are focused on extending patent protection for their products. For instance, in March 2020, Navidea Biopharmaceuticals, Inc. received the U.S. Patent extension for Lymphoseek (technetium [Tc 99m] tilmanocept) until 2025.

Tc-99m can find application in myocardial metabolism imaging. For instance, in November 2019, researchers from Institute of Nuclear and Radiological Sciences and Technology, Greece, reported the synthesis and characterization of two novel derivatives of undecanonoic and hexadecanonoic acid with the aim of developing 99mTc-labeled fatty acids intended for myocardial metabolism imaging.

Regulations                                                         

  • It is essential to attain the approval of the national atomic energy agencies before each step. The supplier has to apply separately to regulatory body for No Objection Certificate / Type Approval for the medical cyclotron.
  • The various stages of clearances needed from national atomic energy agencies which mainly includes:
    • Site Assessment and Approval: The first stage of process is to assess the suitability of the site which includes compliance with the geological and soil characteristics such as seismic condition, geo-hydrology and existing infrastructure etc.
    • Design and Construction Approval: The medical cyclotron should be installed in a room with adequate shielding with adequate isolation and access control. The licensee needs to submit Quality Assurance reports during construction and installation to the concerned regulatory body
    • Commissioning: For granting license for commissioning, the regulatory body evaluates the system performance and the shielding adequacy of the installation
    • Decommissioning: When the medical cyclotron operation is ceased, the permission for decommissioning is required

MEA Technetium-99m Market: Competitive Landscape

Major players operating in MEA technetium-99m market include, GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, Inc., NorthStar Medical Radioisotopes, and Siemens Healthineers.

MEA Technetium-99m Market: Key Developments

Major players in the market are focused on adopting partnership strategies to enhance their market share. For instance, in March 2020, NorthStar Medical Technologies, LLC partnered with Capella Imaging, LLC, a BioGenerator company, under which NorthStar has licensed exclusive rights to FibroScint (Tc-99m F4A), a fibrin-targeted diagnostic imaging agent for cardiac imaging.

Major players in the market are also focused on labeling its products. For instance, in February 2020, BWX Technologies, Inc. successfully labeled technetium-99m derived from its proprietary molybdenum-99 production process and its proprietary Tc-99m generators with cold kits.

Technetium -99m is an isomer of technetium 99, which is used in nuclear medicine and the precursor for technetium-99 is molybdenum-99, a radioactive nuclei generally produced in reactors. Technetium-99m is used as a radioactive tracer and can be detected in body by equipments such as gamma cameras, as Tc-99m emits gamma rays. Technetium-99m, in the form of sodium pertechnetate (Na99mTcO4), is easily obtained from a 99Mo99mTc generator. Sodium Pertechnetate Tc 99m Injection is used in adults as an agent for thyroid imaging, salivary gland imaging, urinary bladder imaging (direct isotopic cystography) for the detection of vesico-ureteral reflux, coronary artery disease, and nasolacrimal drainage system imaging.  

Restraints of the MEA Technetium-99m Market

Major factors hampering the growth of the MEA technetium-99m market during the forecast period constitutes of technetium supply chain issues, and high costs of testing.

Key features of the study:

  • This report provides in-depth analysis of the MEA technetium-99m market and provides market size (US$ Million) and compound annual growth rate (CAGR %) for the forecast period (2019–2027), considering 2018, as the base year
  • It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by leading players
  • It profiles leading players in the MEA technetium-99m market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, Inc., NorthStar Medical Radioisotopes, and Siemens Healthineers.
  • Insights from this report would allow marketers and the management authorities of companies to make informed decision regarding future product launches, technology up-gradation, market expansion, and marketing tactics
  • The MEA technetium-99m market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the market.

Detailed Segmentation

  • MEA Technetium-99m Market, By Isotopic Application:
    • Gamma Camera
    • SPECT
  • MEA Technetium-99m Market, By End User:
    • Hospitals
    • Diagnostic Center
  • MEA Technetium-99m Market, By Country:
    • Saudi Arabia
    • Algeria
    • Bahrain
    • Cyprus
    • Egypt
    • Iran
    • Iraq
    • Israel
    • Jordan
    • Kuwait
    • Lebanon
    • Libya
    • Morocco
    • Mauritania
    • Oman
    • Palestine
    • Qatar
    • Syria
    • Tunisia
    • Turkey
    • Yemen
  • Company Profiles
    • GE Healthcare *
      • Company Overview
      • Product Portfolio
      • Financial Performance
      • Key Strategies
      • Recent Developments
    • IBA
    • Sumitomo Corporation
    • Advanced Cyclotron Systems, Inc.
    • NorthStar Medical Radioisotopes
    • Siemens Healthineers

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objective and Assumption
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Isotopic Application
      • Market Snippet, By End User
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • Regulatory Scenario
  4. MEA Technetium-99m Market, By Isotopic Application, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Gamma Camera
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
    • SPECT
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
      • Segment Trends
  5. MEA Technetium-99m Market, By End User, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Diagnostic Center
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  6. MEA Technetium-99m Market, By Countries, 2017 – 2027 (US$ Mn)
    • Introduction
      • Market Share Analysis, 2019 and 2027 (%)
      • Y-o-Y Growth Analysis, 2019–2027
      • Segment Trends
    • Saudi Arabia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Algeria
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Bahrain
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Cyprus
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Egypt  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Iran
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Iraq
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Israel
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Jordan
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Kuwait
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Lebanon
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Libya
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Morocco
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Mauritania
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Oman
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Palestine
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Qatar
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Syria
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Tunisia
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Turkey
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
    • Yemen
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2019 – 2027, (US$ Mn)
  7. Competitive Landscape
    • Company Profiles
      • GE Healthcare
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • IBA
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Sumitomo Corporation
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Advanced Cyclotron Systems, Inc.
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • NorthStar Medical Radioisotopes
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
      • Siemens Healthineers
        • Company Overview
        • Product Portfolio
        • Key Developments
        • Financial Performance
        • Strategies
  8. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 27 market data tables and 21 figures on “MEA Technetium-99m Market – Global forecast to 2027.

Frequently Asked Questions

MEA technetium-99m market is estimated to account for US$ 394.6 Mn in terms of value and is expected to reach US$ 688.5 Mn by the end of 2027.
Major factor driving the growth of MEA technetium-99m market during the forecast period increasing prevalence of cancer, and technological advancement in imaging techniques.
Major factors hampering the growth of the MEA technetium-99m market during the forecast period constitutes of technetium supply chain issues, and high costs of testing.
Gamma camera held dominant position in the MEA technetium-99m market in 2019.
Egypt technetium-99m market is expected to generate the highest revenue during the forecast period.
Some of the key players operating in the market are GE Healthcare, IBA, Sumitomo Corporation, Advanced Cyclotron Systems, Inc., NorthStar Medical Radioisotopes, and Siemens Healthineers.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner